156
Participants
Start Date
February 22, 2018
Primary Completion Date
December 22, 2023
Study Completion Date
December 22, 2023
Duvelisib
Duvelisib PO 25 mg BID or 50 mg BID or 75 mg BID in 28-day cycles.
Duvelisib
Duvelisib PO 75 mg BID in 28-day cycles.
Duvelisib
Duvelisib PO BID in 28-day cycles (dose determined in Optimization Phase).
Memorial Sloan Kettering Cancer Center, New York
Stony Brook Cancer Center, Stony Brook
University of Rochester, Rochester
UPMC Hillman Cancer Center, Pittsburgh
Ieo, Irccs, Milan
University of Maryland, Baltimore
ASST Papa Giovanni XXIII - Medicina Trasfusionale ed Ematologia - Bergamo, Bergamo
Duke University, Durham
Levine Cancer Institute, Charlotte
Novant Health, Charlotte
Emory University Winship Cancer Institute, Atlanta
A.O.di Bologna Policl.S.Orsola, Bologna
Norton Cancer Institute, Louisville
The Ohio State University, Columbia
Toledo Cancer Center, Toledo
Northwestern University - Feinberg School of Medicine, Chicago
Washington University, St Louis
Baylor Research Institute - Charles Sammons Cancer Center, Dallas
University of California - Los Angeles, Los Angeles
City of Hope National Medical Center, Duarte
University of California - Irvine, Irvine
Dana Farber Cancer Institute, Boston
Universitätsklinikum Carl Gustav Carus, Dresden
Universitätsklinikum Halle (Saale) - Klinik und Poliklinik für Innere Medizin IV, Halle
Policlinico Universitario Agostino Gemelli, Università Cattolica del Sacro Cuore, Roma
Azienda Ospedaliera Santa Maria di Terni, Terni
Japanese Site 8, Fukuoka
Japanese Site 5, Kobe
Japanese Site 3, Miyagi
Japanese Site 6, Nagoya
Japanese Site 7, Niigata
Japanese Site 1, Okayama
Japanese Site 2, Tokyo
Japanese Site 4, Tokyo
Christie Hospital NHS Foundation Trust, Manchester
Nottingham University Hospitals NHS Trust, Nottingham
SecuraBio
INDUSTRY